ImmunityBio (NASDAQ:IBRX) Stock Price Down 8.3% – Here’s Why
by Mitch Edgeman · The Markets DailyImmunityBio, Inc. (NASDAQ:IBRX – Get Free Report) was down 8.3% during mid-day trading on Thursday. The company traded as low as $6.10 and last traded at $6.1170. Approximately 11,675,154 shares changed hands during trading, a decline of 41% from the average daily volume of 19,940,113 shares. The stock had previously closed at $6.67.
ImmunityBio News Roundup
These are some of the IBRX news items that stood out recently:
- Positive Sentiment: BTIG initiated a Buy rating, adding a bullish analyst view. HC Wainwright also maintains a Buy rating and $15 price target. ImmunityBio Gets a Buy from BTIG
- Neutral Sentiment: ImmunityBio plans to present at two London healthcare and biopharma investor conferences during Life Sciences Week. The events may provide an opportunity to discuss its pipeline and commercial progress, but no new results were announced. ImmunityBio to Participate in UK Investor Conferences
- Negative Sentiment: HC Wainwright lowered its earnings estimates across multiple years, including shifting its 2026 forecast to a larger loss and reducing its 2027–2030 projections. The analyst kept a Buy rating and $15 target, but the weaker outlook may weigh on shares. ImmunityBio analyst estimates
Analysts Set New Price Targets
A number of research firms recently issued reports on IBRX. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of ImmunityBio in a report on Tuesday, October 6th. Jefferies Financial Group upped their price target on shares of ImmunityBio from $12.00 to $14.00 and gave the company a “buy” rating in a report on Wednesday, October 14th. HC Wainwright restated a “buy” rating and set a $15.00 price objective on shares of ImmunityBio in a research report on Thursday, October 15th. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $16.00 price objective on shares of ImmunityBio in a research note on Wednesday, October 14th. Six analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $16.00.
Check Out Our Latest Stock Report on ImmunityBio
ImmunityBio Stock Performance
The stock has a 50 day moving average of $8.67 and a two-hundred day moving average of $7.96. The stock has a market cap of $6.43 billion, a PE ratio of -5.61 and a beta of 0.17.
Insider Activity at ImmunityBio
In related news, Director Cheryl Cohen sold 81,056 shares of the firm’s stock in a transaction that occurred on Friday, October 2nd. The shares were sold at an average price of $10.50, for a total value of $851,088.00. Following the completion of the transaction, the director owned 100,309 shares of the company’s stock, valued at approximately $1,053,244.50. This trade represents a 44.69% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Barry Simon sold 25,000 shares of the firm’s stock in a transaction on Monday, October 5th. The stock was sold at an average price of $10.75, for a total value of $268,750.00. Following the completion of the sale, the director directly owned 2,777,788 shares of the company’s stock, valued at approximately $29,861,221. This trade represents a 0.89% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 66.10% of the stock is currently owned by corporate insiders.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Private Advisor Group LLC boosted its stake in shares of ImmunityBio by 433.0% during the 3rd quarter. Private Advisor Group LLC now owns 884,599 shares of the company’s stock valued at $8,351,000 after buying an additional 718,645 shares during the period. Voya Investment Management LLC raised its stake in shares of ImmunityBio by 6.8% during the 3rd quarter. Voya Investment Management LLC now owns 481,693 shares of the company’s stock worth $4,547,000 after purchasing an additional 30,568 shares in the last quarter. Russell Investments Group Ltd. raised its stake in shares of ImmunityBio by 65.5% during the 3rd quarter. Russell Investments Group Ltd. now owns 191,298 shares of the company’s stock worth $1,806,000 after purchasing an additional 75,731 shares in the last quarter. Fifth Third Bancorp lifted its holdings in shares of ImmunityBio by 277.0% during the 3rd quarter. Fifth Third Bancorp now owns 28,277 shares of the company’s stock valued at $267,000 after buying an additional 20,777 shares during the last quarter. Finally, Torrey Growth & Income Advisors lifted its holdings in shares of ImmunityBio by 11.7% during the 3rd quarter. Torrey Growth & Income Advisors now owns 132,775 shares of the company’s stock valued at $1,245,000 after buying an additional 13,915 shares during the last quarter. 8.58% of the stock is owned by hedge funds and other institutional investors.
ImmunityBio Company Profile
ImmunityBio is a biotechnology company that develops immunotherapies for cancer and infectious diseases. Its research combines approaches including immune-modulating biologics, cell therapies and vaccine-based treatments, with a focus on activating the body’s natural and adaptive immune responses. The company’s lead product, Anktiva (nogapendekin alfa inbakicept-pmln), received U.S. Food and Drug Administration approval in 2024 for use with Bacillus Calmette-Guérin (BCG) in adults with BCG-unresponsive non-muscle-invasive bladder cancer with carcinoma in situ, with or without papillary tumors.